SG11201913134UA - Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells - Google Patents

Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells

Info

Publication number
SG11201913134UA
SG11201913134UA SG11201913134UA SG11201913134UA SG11201913134UA SG 11201913134U A SG11201913134U A SG 11201913134UA SG 11201913134U A SG11201913134U A SG 11201913134UA SG 11201913134U A SG11201913134U A SG 11201913134UA SG 11201913134U A SG11201913134U A SG 11201913134UA
Authority
SG
Singapore
Prior art keywords
mitoketoscins
mitochondrial
cancer cells
based therapeutics
therapeutics targeting
Prior art date
Application number
SG11201913134UA
Inventor
Michael Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of SG11201913134UA publication Critical patent/SG11201913134UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/06Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/14Libraries containing macromolecular compounds and not covered by groups C40B40/06 - C40B40/12
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50Molecular design, e.g. of drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Computing Systems (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
SG11201913134UA 2017-06-26 2018-06-25 Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells SG11201913134UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524829P 2017-06-26 2017-06-26
PCT/US2018/039354 WO2019005698A1 (en) 2017-06-26 2018-06-25 Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells

Publications (1)

Publication Number Publication Date
SG11201913134UA true SG11201913134UA (en) 2020-01-30

Family

ID=64742979

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201913134UA SG11201913134UA (en) 2017-06-26 2018-06-25 Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells

Country Status (22)

Country Link
US (2) US11667639B2 (en)
EP (1) EP3644988B1 (en)
JP (1) JP7397672B2 (en)
KR (2) KR102646172B1 (en)
CN (1) CN110913854B (en)
AU (2) AU2018292283B2 (en)
BR (1) BR112019026097A2 (en)
CA (1) CA3064452A1 (en)
CL (1) CL2019003708A1 (en)
CO (1) CO2019014259A2 (en)
CR (1) CR20200033A (en)
CU (1) CU20190106A7 (en)
DO (2) DOP2019000312A (en)
EC (1) ECSP20001729A (en)
IL (2) IL292109B2 (en)
MX (1) MX2019014806A (en)
PE (1) PE20200295A1 (en)
PH (1) PH12019502892A1 (en)
RU (1) RU2020102908A (en)
SG (1) SG11201913134UA (en)
WO (1) WO2019005698A1 (en)
ZA (2) ZA201907831B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075226A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
BR112020008505A2 (en) * 2017-11-03 2020-10-20 Bioimics Ab anti-infectious heterocyclic compounds and their uses
BR112021006423A2 (en) 2018-10-02 2021-07-06 Lunella Biotech Inc azithromycin and roxithromycin derivatives as senolitic drugs
WO2020242857A1 (en) 2019-05-24 2020-12-03 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
FR2674522B1 (en) 1991-03-26 1993-07-16 Lipha NOVEL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICAMENTS CONTAINING THEM.
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
NZ304095A (en) 1995-05-03 1998-10-28 Pfizer 9-(substituted acylamino) tetracyclic derivatives and medicaments
WO1999026582A2 (en) 1997-11-25 1999-06-03 University Of Otago Mitochondrially targeted compounds
PT941998E (en) 1998-03-03 2004-12-31 Pfizer Prod Inc MACROLIDAN ANTIBIOTICS OF TYPE 3,6-CETAL
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
EP2517729A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
MY140849A (en) 2003-07-07 2010-01-29 Kowa Co 2, 4-bis (trifluoroethoxy) pyridine compound and drug containing the compound
WO2005062851A2 (en) 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
CA2557216A1 (en) 2004-02-26 2005-09-09 Advanced Ocular Systems Limited Heparin for the treatment of ocular pathologies
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ATE523519T1 (en) 2005-01-14 2011-09-15 Glaxo Group Ltd MACROLIDE COMPOUNDS WITH BIOTIN AND PHOTO AFFINITY GROUP FOR IDENTIFYING A MACROLIDE TARGET
RU2447889C2 (en) 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Method of treating cancer (versions)
WO2007139930A2 (en) 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
US20090311249A1 (en) 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
WO2007147023A1 (en) 2006-06-14 2007-12-21 Bristol-Myers Squibb Company An assay for measuring acyltransferase activity
WO2008054726A2 (en) 2006-10-30 2008-05-08 Southern Research Institute Targeting nbs1-atm interaction to sensitize cancer cells to radiotherapy and chemotherapy
LT2117520T (en) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
US8647673B2 (en) 2007-07-24 2014-02-11 Wayne State University Nanoparticles for imaging and treating chlamydial infection
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
WO2009045443A2 (en) 2007-10-02 2009-04-09 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
BRPI1014978A2 (en) 2009-04-17 2019-07-02 Colby Pharmaceutical Company cancer treatment method and pharmaceutical composition.
CN102439453A (en) 2009-05-20 2012-05-02 日内瓦大学 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
EP2506840B1 (en) 2009-12-04 2021-01-06 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors
US8673587B2 (en) 2010-05-04 2014-03-18 Trustees Of Dartmouth College Methods for identifying allosteric and other novel acyl-coenzyme A:cholesterol acyltransferase inhibitors
CA2808859A1 (en) 2010-08-20 2012-02-23 Pangea Biosciences, Inc. Cancer diagnostic and cancer therapeutic
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
US20130172430A1 (en) 2010-12-10 2013-07-04 Michael P. Lisanti Prognosis and treatment of breast cancer
EA032840B8 (en) 2011-06-22 2020-06-18 Вайоми Терапеутикс Лимитед Conjugate-based antifungal prodrugs and use thereof
ES2627120T3 (en) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medication for the treatment of liver cancer
US9801922B2 (en) 2011-08-03 2017-10-31 University Of Iowa Research Foundation Compositions and methods of treating cancer
US9180134B2 (en) 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
SG11201400456RA (en) * 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
WO2013040206A1 (en) 2011-09-14 2013-03-21 Lewis Thomas J Novel formulations comprising macrolide and tetracycline and their uses
CA2866080C (en) 2012-03-01 2021-01-19 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics
US9526795B2 (en) 2012-08-28 2016-12-27 Annam Biosciences, Llc N-BOC-dendrimers and their conjugates
WO2014036654A1 (en) 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
EP3016715A4 (en) 2013-07-01 2017-02-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
US20150231069A1 (en) 2014-02-20 2015-08-20 Pankaj Modi Oral formulations of chemotherapeutic agents
US20170224730A1 (en) 2014-06-10 2017-08-10 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
US10413558B2 (en) 2014-10-17 2019-09-17 Targeted Therapies Research And Consulting Center Sprl Multi-ingredient pharmaceutical composition for use in cancer therapy
JP6439931B2 (en) 2015-02-26 2018-12-19 大日本印刷株式会社 Adsorption conveyance device and adsorption conveyance method
RU2727474C2 (en) 2015-10-06 2020-07-21 Редхилл Байофарма Лтд. Types of combined therapy for cancer treatment
US11725041B2 (en) 2016-08-11 2023-08-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
WO2018136598A1 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
US20200121739A1 (en) 2017-01-18 2020-04-23 Evelo Biosciences, Inc. Bacteria for treating cancer
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
EP3624840A4 (en) 2017-05-19 2021-03-10 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
EP3624897A4 (en) 2017-05-19 2021-07-14 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy

Also Published As

Publication number Publication date
JP7397672B2 (en) 2023-12-13
PE20200295A1 (en) 2020-02-05
PH12019502892A1 (en) 2020-12-07
EP3644988A1 (en) 2020-05-06
ECSP20001729A (en) 2020-02-28
IL292109B2 (en) 2024-02-01
AU2018292283B2 (en) 2020-07-23
IL270774A (en) 2020-01-30
JP2020525009A (en) 2020-08-27
US20200148688A1 (en) 2020-05-14
RU2020102908A3 (en) 2021-11-15
IL292109A (en) 2022-06-01
CN110913854B (en) 2023-04-28
MX2019014806A (en) 2020-02-10
EP3644988A4 (en) 2021-03-03
EP3644988B1 (en) 2023-02-22
CA3064452A1 (en) 2019-01-03
WO2019005698A1 (en) 2019-01-03
US11667640B2 (en) 2023-06-06
BR112019026097A2 (en) 2020-07-07
DOP2022000142A (en) 2022-09-30
KR20200018814A (en) 2020-02-20
AU2020257159A1 (en) 2020-11-19
RU2020102908A (en) 2021-07-27
KR102646172B1 (en) 2024-03-13
ZA201907831B (en) 2022-07-27
KR20240038805A (en) 2024-03-25
IL292109B1 (en) 2023-10-01
CR20200033A (en) 2020-03-05
CU20190106A7 (en) 2020-11-30
CL2019003708A1 (en) 2020-05-15
AU2018292283A1 (en) 2019-12-12
AU2020257159B2 (en) 2022-07-14
CN110913854A (en) 2020-03-24
DOP2019000312A (en) 2020-03-15
CO2019014259A2 (en) 2020-04-01
ZA202101954B (en) 2022-09-28
US11667639B2 (en) 2023-06-06
US20200207775A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
IL292109A (en) Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
EP3193914A4 (en) Organ protection in psma-targeted radionuclide therapy of prostate cancer
EP3186393A4 (en) Methods and compositions related to prostate cancer therapeutics
HK1249852A1 (en) Nk-92 cells in combination therapy with cancer drugs
EP3362248A4 (en) Molded pocket in transaction card construction
PL3409083T4 (en) Improvements in and relating to data centres
HK1246165A1 (en) Agent for enhancing atp in cells
EP3781196C0 (en) Sequence-specific in vivo cell targeting
EP3166616A4 (en) Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
ZA202101517B (en) Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
GB2544569B (en) Improvements in tablet manufacture
EP3314250A4 (en) Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
HK1251013A1 (en) Histamine-producing bacterial strains and their use in cancer
HK1252038A1 (en) Gene expression profiles and uses thereof in breast cancer
GB201521304D0 (en) Tokenisation in cardholder - not - present transactions
GB201510288D0 (en) Improvements in dosimetry techniques for radiotherapy
IL255560A (en) Macropinocytosis in cancer
SG11202004861UA (en) Chimeric molecule for targeting c-myc in cells
EP3532638A4 (en) Targeting microrna-101-3p in cancer therapy
EP3448401A4 (en) Hsv vectors with enhanced replication in cancer cells
GB201702130D0 (en) Improvements in or relating to currency conversion
AU2016904353A0 (en) Improvements in or relating to transactions
GB201522573D0 (en) Cancer therapeutics
AU2016901636A0 (en) Improvements in water heating elements
AU2015901565A0 (en) Improvements in Water Heating Elements